Mercer Global Advisors
AKTS

Mercer Global Advisors’s Aktis Oncology AKTS Stock Holding History

Mercer Global Advisors’s Portfolio AKTS Stock Details AKTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$96K Buy
+2,978
New +$61.2K ﹤0.01% 3864

Other funds holding AKTS

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Mercer Global Advisors's AKTS Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Aktis Oncology (AKTS) in Q2 2026: 2,978 shares worth $96K. The stake represents ﹤0.01% of the portfolio and ranks #3864 among its holdings.

106 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

  • Mercer Global Advisors held 2,978 shares of Aktis Oncology worth $96K as of Q2 2026.
  • Aktis Oncology was a new Mercer Global Advisors position in Q2 2026.
  • Aktis Oncology made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3864 holding.
  • 106 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.